Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BLCO NASDAQ:ESTA NASDAQ:LQDA NYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$15.95-1.3%$16.18$10.99▼$18.92$5.69B0.59426,867 shs116,143 shsESTAEstablishment Labs$71.68+0.6%$64.47$33.35▼$83.31$2.11B1.12507,359 shs173,990 shsLQDALiquidia$61.89-0.1%$41.61$11.85▼$62.30$5.51B0.411.70 million shs490,620 shsSTVNStevanato Group€18.08+1.3%€15.62€12.89▼€28.00€5.46B0.75639,236 shs96,432 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb-0.16%-0.66%+0.68%-9.97%+43.71%ESTAEstablishment Labs+1.70%+2.05%+11.19%-6.28%+98.52%LQDALiquidia+0.32%+4.50%+70.95%+84.49%+271.97%STVNStevanato Group+0.34%-0.13%+16.26%+11.43%-25.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCOBausch + Lomb$15.95-1.3%$16.18$10.99▼$18.92$5.69B0.59426,867 shs116,143 shsESTAEstablishment Labs$71.68+0.6%$64.47$33.35▼$83.31$2.11B1.12507,359 shs173,990 shsLQDALiquidia$61.89-0.1%$41.61$11.85▼$62.30$5.51B0.411.70 million shs490,620 shsSTVNStevanato Group€18.08+1.3%€15.62€12.89▼€28.00€5.46B0.75639,236 shs96,432 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCOBausch + Lomb-0.16%-0.66%+0.68%-9.97%+43.71%ESTAEstablishment Labs+1.70%+2.05%+11.19%-6.28%+98.52%LQDALiquidia+0.32%+4.50%+70.95%+84.49%+271.97%STVNStevanato Group+0.34%-0.13%+16.26%+11.43%-25.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCOBausch + Lomb 2.21Hold$18.0813.41% UpsideESTAEstablishment Labs 2.63Moderate Buy$87.1421.57% UpsideLQDALiquidia 2.92Moderate Buy$49.33-20.29% DownsideSTVNStevanato Group 2.40HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ESTA, BLCO, STVN, and LQDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026LQDALiquidia HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$55.00 ➝ $67.005/12/2026LQDALiquidia Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$51.00 ➝ $62.005/11/2026LQDALiquidia Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/11/2026LQDALiquidia Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$54.00 ➝ $70.005/11/2026LQDALiquidia BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $59.005/7/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$88.00 ➝ $90.005/6/2026ESTAEstablishment Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/5/2026LQDALiquidia Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/30/2026BLCOBausch + Lomb Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$16.004/29/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/21/2026LQDALiquidia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCOBausch + Lomb$5.10B1.11$1.64 per share9.71$18.09 per share0.88ESTAEstablishment Labs$211.08M9.99N/AN/A$0.50 per share143.36LQDALiquidia$158.32M34.76N/AN/A$1.22 per share50.73STVNStevanato Group€1.20B4.55€0.90 per share20.12€5.92 per share3.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCOBausch + Lomb-$360M-$0.62N/A14.760.50-4.21%3.60%1.69%7/29/2026 (Estimated)ESTAEstablishment Labs-$51.06M-$1.49N/A512.01N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)LQDALiquidia-$68.92M$0.14442.4212.87N/A7.74%46.82%7.06%N/ASTVNStevanato Group€158.21M€0.5930.5622.611.6411.76%10.27%6.08%N/ALatest ESTA, BLCO, STVN, and LQDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LQDALiquidia$0.4102$0.52+$0.1098$0.52$119.44 million$132.87 million5/8/2026Q1 2026STVNStevanato Group€0.12€0.11-€0.01€0.10N/A€273.57 million5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million4/29/2026Q1 2026BLCOBausch + Lomb$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion3/18/2026Q4 2025LQDALiquidia$0.01$0.15+$0.14N/AN/AN/A3/5/2026Q4 2025LQDALiquidia$0.08$0.15+$0.07$0.15$87.49 million$92.02 million2/24/2026Q4 2025ESTAEstablishment Labs-$0.22-$0.09+$0.13-$0.09$63.80 million$64.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLCOBausch + LombN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ALQDALiquidiaN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCOBausch + Lomb0.781.530.99ESTAEstablishment Labs16.822.961.91LQDALiquidia1.182.222.03STVNStevanato Group0.211.631.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCOBausch + Lomb11.07%ESTAEstablishment Labs72.91%LQDALiquidia64.54%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipBLCOBausch + Lomb1.45%ESTAEstablishment Labs9.99%LQDALiquidia25.60%STVNStevanato Group0.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLCOBausch + Lomb13,000356.57 million351.40 millionOptionableESTAEstablishment Labs1,00429.43 million26.49 millionOptionableLQDALiquidia5088.93 million66.16 millionOptionableSTVNStevanato Group6,010302.84 million300.72 millionOptionableESTA, BLCO, STVN, and LQDA HeadlinesRecent News About These CompaniesStevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comStevanato Group SpA (STVN)May 10, 2026 | investing.comStevanato Group Margin Momentum Draws Fresh Market AttentionMay 10, 2026 | kalkinemedia.comKEarnings Beat: Stevanato Group S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 9, 2026 | finance.yahoo.comStevanato Group (NYSE:STVN) Issues Earnings Results, Misses Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comA Look At Stevanato Group’s (NYSE:STVN) Valuation After Its Recent Share Price ReboundMay 7, 2026 | finance.yahoo.comStevanato maintains 2026 guidance of €1.260B-€1.290B revenue as it targets RTU cartridge production in early 2027May 7, 2026 | msn.comStevanato Group Files Form 6-K Detailing Q1 2026 Results PresentationMay 7, 2026 | tipranks.comStevanato Group S.p.A. (STVN) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comStevanato Group (STVN) Q1 Earnings and Revenues Beat EstimatesMay 7, 2026 | zacks.comStevanato Group (NYSE:STVN) Releases FY 2026 Earnings GuidanceMay 7, 2026 | marketbeat.comStevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026May 7, 2026 | businesswire.comStevanato Group to Participate in Three Upcoming Investor ConferencesMay 4, 2026 | businesswire.comStevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of "Hold" by BrokeragesMay 4, 2026 | marketbeat.comJennison Associates LLC Buys 213,602 Shares of Stevanato Group S.p.A. $STVNMay 2, 2026 | marketbeat.comStevanato Group S.p.A. $STVN Shares Sold by Conestoga Capital Advisors LLCMay 1, 2026 | marketbeat.comStevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings GrowthApril 30, 2026 | zacks.comStevanato Group (NYSE:STVN) Volume Surge Sparks Market FocusApril 29, 2026 | kalkinemedia.comKStevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume - Should You Buy?April 29, 2026 | marketbeat.comHere’s Why Stevanato Group Spa (STVN) Declined in Q1April 28, 2026 | finance.yahoo.comStevanato Group to Report First Quarter 2026 Financial Results on May 7, 2026April 23, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026Did Qualcomm Just Put Apple in Check?By Jeffrey Neal Johnson | April 28, 2026Does Cheesecake Factory Stock Have Any Upside Left on the Menu?By Jennifer Ryan Woods | April 27, 2026Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageBy Jeffrey Neal Johnson | May 6, 2026Freeport-McMoRan: Grasberg Restarts, Now the Real Work BeginsBy Chris Markoch | April 24, 2026ESTA, BLCO, STVN, and LQDA Company DescriptionsBausch + Lomb NYSE:BLCO$15.94 -0.21 (-1.27%) As of 02:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Establishment Labs NASDAQ:ESTA$71.68 +0.45 (+0.63%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.Liquidia NASDAQ:LQDA$61.89 -0.08 (-0.13%) As of 02:40 PM Eastern This is a fair market value price provided by Massive. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Stevanato Group NYSE:STVN€18.08 +0.23 (+1.31%) As of 02:39 PM Eastern This is a fair market value price provided by Massive. Learn more.Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
